Published in Women's Health Weekly, May 1st, 2006
Researchers in the United States and Italy conducted a study "to evaluate the potential of human papillomavirus (HPV) type 16 and 18 E7 antigen-loaded autologous dendritic cells (DC) as a therapeutic cellular vaccine in a case series of cervical cancer patients harboring recurrent/metastatic disease refractory to standard treatment modalities."
"Autologous monocyte-derived DC were pulsed with recombinant HPV16 E7 or HPV18 E7 oncoproteins and administered to four cervical cancer patients," said Alessandro D. Santin and collaborators at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly